Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could your gut and kidneys affect your brain? new study explores link in kidney disease

NCT ID NCT07617402

First seen Jun 02, 2026 · Last updated Jun 22, 2026 · Updated 7 times

Summary

This completed study looked at why people with IgA nephropathy (a kidney disease) often experience memory and thinking problems. Researchers used advanced MRI scans, along with blood and stool samples, to examine connections between the brain, gut, and kidneys in 100 patients and 100 healthy volunteers. The goal was to identify possible causes of cognitive decline in this condition, which could lead to better treatments in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Functional and Molecular Imaging Key Lab of Shaanxi Province, Department of Radiology, Tangdu Hospital, Fourth Military Medical University

    Shanxi, Xi'an, 713800, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this research could point toward new ways to detect or treat cognitive decline in IgA nephropathy patients by targeting the brain-gut-kidney axis.

What could go wrong

This is an observational study, not a treatment trial. It aims to understand mechanisms, not test a therapy. Results may not lead directly to clinical changes.

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.